scholarly journals Lymphocytic Mastopathy – A Rare Entity and A Diagnostic Challenge

Author(s):  
Maria Julia Corbetta Machado ◽  
Guillermo Regalo ◽  
Maria Julia Corbetta Machado

Lymphocytic mastopathy is a benign rare entity, commonly associated with long standing diabetes. It has also rarely been reported on patients with autoimmune diseases, particularly Sjogren’s syndrome. There are very few cases reported, with the literature suggesting an incidence of <1% of benign breast diseases. Despite being considered a benign disease, lymphocytic mastopathy presents similarly to breast cancer on imaging, posing a diagnostic challenge. This report describes a case of a postmenopausal woman with significant autoimmune history that presented with a right-sided breast lump found to have lymphocytic mastopathy on histology.

1992 ◽  
Vol 135 (6) ◽  
pp. 619-631 ◽  
Author(s):  
Nancy Krieger ◽  
Robert A. Hiatt

GYNECOLOGY ◽  
2021 ◽  
Vol 23 (1) ◽  
pp. 48-54
Author(s):  
Izabella P. Aminodova ◽  
Elizaveta V. Perminova

Aim. To assess the effectiveness of a comprehensive examination of women of different ages in the diagnosis of benign breast diseases and breast cancer (BC). Materials and methods. Retrospective analysis of medical records (600 cases), questionnaires of 300 women, prospective analysis of the results of a comprehensive examination of 300 patients. Results. The link between low screening coverage and insufficient activity and awareness of the population has been established. The significance of various risk factors, including reproductive history, lifestyle, use of hormone therapy and heredity, for benign breast diseases and BC, has been clarified. It was shown that breast diseases are often combined with endometrial hyperplastic processes, uterine myoma, menstrual dysfunctions, severe lesions of the cervical epithelium and neuroendocrine diseases. The diagnostic efficiency of different examination methods and their combined use for the timely identification of BC and differential diagnosis of benign and malignant breast diseases has been clarified. A high frequency of faults in the preparation of primary medical documentation was revealed, that impedes adequate assessment of risk factors and the formation of group for dispensary follow-up. Conclusion. It is necessary to correct measures for the secondary prevention of BC, including the formation, registration and dynamic follow-up of a cohort of women with a high risk for BC. One of the options for solving the issue of inadequate diagnosis for breast tumors can be a complex multiparametric approach to assessing the reproductive system, including the assessment of risk factors, the combined use of ultrasound and X-ray examination methods, which makes it possible to increase the accuracy of primary and differential diagnostics, and the development of a personalized follow-up algorithm for women with high risk for benign breast diseases and BC.


2017 ◽  
Vol 6 (6) ◽  
pp. 1482-1489 ◽  
Author(s):  
Margarita Posso ◽  
Josep M. Corominas ◽  
Laia Serrano ◽  
Marta Román ◽  
Isabel Torá-Rocamora ◽  
...  

2010 ◽  
Vol 5 (1) ◽  
pp. 38-46 ◽  
Author(s):  
Beata Olas ◽  
Magdalena Kedzierska ◽  
Barbara Wachowicz ◽  
Anna Stochmal ◽  
Wieslaw Oleszek ◽  
...  

AbstractThe various specific biomarkers of oxidative stress in plasma from patients with breast cancer, as well as biomarkers (the level of lipid hydroperoxides, conjugated dienes, thiobarbituric acid reactive substances) have been described. The aim of our present study was to evaluate the amount of low-molecular-weight thiols (which are physiological free radical scavengers) and establish the effects of the extract from A. melanocarpa on the amount of these thiols in plasma obtained from patients with invasive breast cancer, patients with benign breast diseases and from healthy volunteers. We observed in patients the higher amounts of homocysteine in plasma from patients in comparison to plasma from the control group; however the total level of glutathione, cysteine, cysteinylglycine, and the amount of thiols in reduced and oxidized forms was changed (e.g., in patients, the decrease of glutathione and cysteine reached about 50% of total values). Moreover, we showed that in the presence of the extract of A. melanocarpa (50 µg/mL, 5 min, 37°C), changes in amount of thiols in plasma from patients with invasive breast cancer and patients with benign breast diseases were significantly reduced in vitro. Considering the data presented in this study, we suggest that the extract from A. melanocarpa has an effect on thiol metabolism and the levels of all tested thiols observed in plasma obtained from breast cancer patients.


2007 ◽  
Vol 108 (3) ◽  
pp. 427-434 ◽  
Author(s):  
Chuanzhong Ye ◽  
Xiao-Ou Shu ◽  
Wanqing Wen ◽  
Larry Pierce ◽  
Regina Courtney ◽  
...  

2021 ◽  
Vol 4 (6) ◽  
pp. e2114716
Author(s):  
Annelie Johansson ◽  
Athanasia E. Christakou ◽  
Adina Iftimi ◽  
Mikael Eriksson ◽  
Jose Tapia ◽  
...  

2003 ◽  
Vol 107 (5) ◽  
pp. 817-821 ◽  
Author(s):  
Areti Lagiou ◽  
Pagona Lagiou ◽  
Dorothy-Stamatia Vassilarou ◽  
Melpomeni Stoikidou ◽  
Dimitrios Trichopoulos

Sign in / Sign up

Export Citation Format

Share Document